Using artificial intelligence to discover therapeutic antibodies
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advan…
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advan…
Messenger RNA (mRNA) nanomedicines, a ground-breaking technology that has led to the development of the first approved C…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-cl…
. Heidelberg Pharma präsentiert initiale Ergebnisse der ersten klinischen Studie mit dem ATAC®-Kandidaten HDP-101 Lize…
Die Heidelberg Pharma AG (FWB: HPHA) gab heute bekannt, dass ihre Tochtergesellschaft Heidelberg Pharma Research GmbH un…
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potentia…
Zwei Impfungen mit Comirnaty führen nicht zu adäquaten Antikörperspiegeln gegen die SARS-CoV-2-Virusvariante Omikron. Ei…
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination…
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…